|Bid||58.65 x 800|
|Ask||61.07 x 2200|
|Day's range||58.76 - 60.38|
|52-week range||58.54 - 86.29|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||36.30|
|Earnings date||30 Oct 2023 - 03 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||83.06|
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
WILMINGTON, Del., August 22, 2023--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September: